What is the current Gene Therapy on Cancer market size?

The Gene Therapy on Cancer market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Gene Therapy on Cancer market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Gene Therapy on Cancer market?

Key drivers include advancements in technology and rising cancer incidence, fueling the future outlook.

What challenges does the Gene Therapy on Cancer market face?

Challenges include high development costs and regulatory hurdles, impacting market growth.

Which regions are leading the Gene Therapy on Cancer market?

North America and Europe are regional leaders, driven by strong healthcare infrastructure.

Who are the top companies in the Gene Therapy on Cancer market?

Top companies include pharmaceutical giants and biotech firms, such as Novartis and Gilead Sciences.

What future opportunities exist in the Gene Therapy on Cancer market?

Future opportunities include emerging markets and innovative treatments, shaping the market's future outlook.

How is technology impacting the Gene Therapy on Cancer market?

Technology is advancing gene editing techniques, enhancing treatment efficacy and safety.

What is the current regulatory landscape for Gene Therapy on Cancer?

The regulatory landscape is evolving, with ongoing updates to guidelines and approvals for new treatments.

What is the expected impact of Gene Therapy on Cancer on the overall oncology market?

Gene Therapy on Cancer is expected to significantly impact the oncology market, offering new treatment options.

Gene Therapy on Cancer Industry Size, Share & Growth Forecast 2033

Gene Therapy on Cancer by Application (Hospital, Clinic, Other), by Types (Viral Gene Therapy, Non-viral Gene Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gene Therapy on Cancer Market Overview

The Gene Therapy on Cancer market involves the use of genes to treat or prevent cancer, and its relevance is growing due to its potential to revolutionize cancer treatment. As the Gene Therapy on Cancer market size is expected to reach $14.1 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion. The scope of this market encompasses various types of gene therapies, including immunotherapy, oncolytic virus therapy, and gene editing, with applications in hospitals, research institutions, and pharmaceutical companies. The current Gene Therapy on Cancer market size is approximately $4.8 billion, and it is expected to grow at a CAGR of 15.1% during the forecast period, driven by macro drivers such as increasing cancer prevalence, advances in gene editing technologies, and rising investments in cancer research.

Loading chart…

The Gene Therapy on Cancer market is shaped by key forces such as technology shifts, including the development of new gene editing tools like CRISPR, regulations, such as those related to clinical trial approvals and drug pricing, and consumer behavior, including increasing awareness and demand for innovative cancer treatments. The largest region in the Gene Therapy on Cancer market is North America, while the fastest-growing region is Asia-Pacific, driven by rising investments in cancer research and growing demand for advanced cancer treatments. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest developments and trends to capitalize on emerging opportunities and stay ahead of the competition.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Gilead Sciences; Amgen; Shanghai Sunway; Sibiono; Segene Inc.; CRISPR Therapeutics; Bluebird Bio; Sangamo Therapeutics; Editas Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gene Therapy on Cancer market is poised for significant growth, driven by advancements in genetic engineering and increasing demand for targeted cancer treatments. The Gene Therapy on Cancer market size is expected to expand substantially, with a promising growth forecast, as researchers and pharmaceutical companies invest heavily in developing innovative gene therapies.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR/Cas9, have improved the precision and efficacy of gene therapy, enabling the development of more targeted and effective cancer treatments

Rising cancer incidence rates and the need for more effective treatments are driving demand for gene therapy, contributing to the growth of the Gene Therapy on Cancer market

Restraints2 items

High development costs and regulatory hurdles are limiting the pace of innovation in the Gene Therapy on Cancer market, making it challenging for companies to bring new treatments to market

The complexity of gene therapy manufacturing processes is a significant restraint, as it requires specialized facilities and expertise, increasing production costs and limiting supply

Opportunities2 items

The growing demand for personalized medicine is creating opportunities for gene therapy companies to develop targeted treatments tailored to individual patients' needs, driving growth in the Gene Therapy on Cancer market size

Strategic partnerships between gene therapy companies and pharmaceutical firms are enabling the development of new treatments and expanding the reach of gene therapy, contributing to a positive growth forecast

Challenges2 items

Ensuring the long-term safety and efficacy of gene therapies is a significant challenge, as the technology is still evolving and there is limited data on long-term outcomes

The reimbursement landscape for gene therapies is uncertain, with many payers hesitant to cover the high costs of these treatments, limiting access and adoption

Market Segmentation

Loading chart…

The Gene Therapy on Cancer market can be segmented based on Application, which includes various types of cancer such as lung cancer, breast cancer, leukemia, and others. This segmentation is crucial in understanding the Gene Therapy on Cancer segmentation and its impact on the overall market size. The application segment contributes significantly to the market size, as different types of cancer require specific gene therapy approaches.

Another important segmentation category is Types, which includes ex vivo and in vivo gene therapy. Ex vivo gene therapy involves removing cells from the body, modifying them genetically, and then reinserting them, while in vivo gene therapy involves directly introducing the gene into the body. Understanding the market taxonomy of these subtypes is essential to determine their contribution to the overall Gene Therapy on Cancer market size.

Gene Therapy on Cancer Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Viral Gene Therapy

Non-viral Gene Therapy

Regional Insights

Loading chart…

The Gene Therapy on Cancer market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of gene therapy, favorable policies, and significant investments in the healthcare sector.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong regulatory framework, increasing investments in research and development, and a growing patient population. Asia Pacific's growth is fueled by a large and growing patient population, increasing adoption of innovative therapies, and significant investments in healthcare infrastructure.

Latin America and Middle East & Africa are also expected to contribute to the Gene Therapy on Cancer market growth, driven by increasing awareness, improving infrastructure, and growing demand for innovative therapies. The regional forecast indicates that these regions will play a crucial role in the market's growth, with Latin America accounting for around 10% and Middle East & Africa accounting for around 5% of the market share.

Competitive Landscape

The Gene Therapy on Cancer market is moderately consolidated, driven by a mix of global players and local/regional companies. The Gene Therapy on Cancer competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on product innovation and regulatory approvals to maintain their market position, while local/regional companies are emphasizing distribution and pricing strategies to compete.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies must focus on strategic initiatives that drive growth and differentiation.

Novartis: regional expansion

Gilead Sciences: innovation pipeline

Amgen: premium pricing

Shanghai Sunway: local manufacturing

Sibiono: OEM tie-ups

CRISPR Therapeutics: vertical integration

Key Gene Therapy on Cancer Companies10 items

Novartis

Gilead Sciences

Amgen

Shanghai Sunway

Sibiono

Segene Inc.

CRISPR Therapeutics

Bluebird Bio

Sangamo Therapeutics

Editas Medicine

Market Ecosystem

The Gene Therapy on Cancer ecosystem encompasses a complex network of participants, spanning from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three primary categories: upstream, midstream, and downstream. Upstream participants, such as technology providers and suppliers, contribute to the development of gene therapy technologies and components. Midstream participants, including system integrators and manufacturers, integrate these components into functional gene therapy products. Downstream participants, comprising distributors, service providers, and end users, facilitate the delivery and adoption of these products. The value created and captured within this ecosystem is influenced by the interactions and interdependencies among these participants.

Technology providers — develop gene editing tools

Raw material/component suppliers — provide vectors and nucleic acids

System integrators / EPCs — design and manufacture gene therapy products

Distributors / channel partners — facilitate product delivery to healthcare providers

Service providers / after-sales — offer support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish and enforce safety and efficacy standards

Within the Gene Therapy on Cancer ecosystem, control points, such as regulatory approvals and standards, significantly influence the adoption of gene therapies. Dependency risks, including input constraints and approvals, can also impact the ecosystem's functioning. Furthermore, switching costs, partnerships, and interoperability requirements can affect the dynamics among participants. As the ecosystem differs by region, due to varying regulatory frameworks and healthcare systems, a comprehensive value chain analysis is essential to understanding the intricacies of the Gene Therapy on Cancer ecosystem and identifying opportunities for growth and collaboration.

Recent Industry Insights

The Gene Therapy on Cancer industry has witnessed significant developments over the last 12-18 months, shaping the Gene Therapy on Cancer industry trends. Recent partnerships between pharmaceutical companies and research institutions have accelerated the development of innovative treatments. Notable mergers and acquisitions have also taken place, allowing companies to expand their portfolios and enhance their capabilities. Additionally, several product and technology launches have been announced, showcasing promising results in clinical trials.

Furthermore, regulatory changes have created a more favorable environment for the development and approval of gene therapies. A shift in consumer and enterprise trends has also been observed, with increased focus on personalized medicine and targeted treatments. Several funding rounds and expansions have been reported, providing companies with the necessary resources to advance their research and development efforts, ultimately driving growth in the Gene Therapy on Cancer industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Gene Therapy on Cancer market outlook. The market attractiveness is high due to the increasing prevalence of cancer and the growing demand for innovative treatments. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term outlook is positive, driven by advancements in gene editing technologies and the potential for curative treatments.

The innovation landscape is dynamic, with emerging technologies such as CRISPR/Cas9 gene editing. However, the demand–supply balance is a key risk factor, as the high cost of gene therapies may limit accessibility. Overall, the Gene Therapy on Cancer market is poised for significant growth, but stakeholders must navigate these challenges to capitalize on the opportunities.

11 items

1. Executive Summary

2. Gene Therapy on Cancer Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gene Therapy on Cancer Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gene Therapy on Cancer Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Other

6.2. Global Gene Therapy on Cancer Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Viral Gene Therapy

6.2.2. Non-viral Gene Therapy

6.3. Global Gene Therapy on Cancer Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gene Therapy on Cancer Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gene Therapy on Cancer Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gene Therapy on Cancer Market Competition by Key Manufacturers

8.1. Global Gene Therapy on Cancer Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gene Therapy on Cancer: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Gilead Sciences

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Amgen

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Shanghai Sunway

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sibiono

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Segene Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CRISPR Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bluebird Bio

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sangamo Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Editas Medicine

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gene Therapy on Cancer Market

Figure 4: Global Gene Therapy on Cancer Market: Drivers

Figure 5: Global Gene Therapy on Cancer Market: Challenges

Figure 6: Global Gene Therapy on Cancer Market: Trends

Figure 7: Global Gene Therapy on Cancer Market: Opportunity

Figure 8: Global Gene Therapy on Cancer Market: Restraint

Figure 9: Global Gene Therapy on Cancer Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gene Therapy on Cancer Market Value (USD Million) By Region

Figure 15: Global Gene Therapy on Cancer Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gene Therapy on Cancer Market Value (USD Million) By Region

Figure 23: Global Gene Therapy on Cancer Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Gene Therapy on Cancer Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gene Therapy on Cancer Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gene Therapy on Cancer Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gene Therapy on Cancer Market Value (USD Million) By Region

Table 10: Global Gene Therapy on Cancer Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gene Therapy on Cancer Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gene Therapy on Cancer Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gene Therapy on Cancer Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Gilead Sciences Basic Information And Sales Area

Table 33: Gilead Sciences. Products Portfolio

Table 34: Amgen Basic Information And Sales Area

Table 35: Amgen. Products Portfolio

Table 36: Shanghai Sunway Basic Information And Sales Area

Table 37: Shanghai Sunway. Products Portfolio

Table 38: Sibiono Basic Information And Sales Area

Table 39: Sibiono. Products Portfolio

Table 40: Segene Inc. Basic Information And Sales Area

Table 41: Segene Inc.. Products Portfolio

Table 42: CRISPR Therapeutics Basic Information And Sales Area

Table 43: CRISPR Therapeutics. Products Portfolio

Table 44: Bluebird Bio Basic Information And Sales Area

Table 45: Bluebird Bio. Products Portfolio

Table 46: Sangamo Therapeutics Basic Information And Sales Area

Table 47: Sangamo Therapeutics. Products Portfolio

Table 48: Editas Medicine Basic Information And Sales Area

Table 49: Editas Medicine. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Gene Therapy on Cancer Market Value (USD Million) By Region

Table 55: Global Gene Therapy on Cancer Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Gene Therapy on Cancer Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	38.29 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Gilead Sciences; Amgen; Shanghai Sunway; Sibiono; Segene Inc.; CRISPR Therapeutics; Bluebird Bio; Sangamo Therapeutics; Editas Medicine
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR/Cas9, have improved the precision and efficacy of gene therapy, enabling the development of more targeted and effective cancer treatments

Rising cancer incidence rates and the need for more effective treatments are driving demand for gene therapy, contributing to the growth of the Gene Therapy on Cancer market

Restraints2 items

High development costs and regulatory hurdles are limiting the pace of innovation in the Gene Therapy on Cancer market, making it challenging for companies to bring new treatments to market

The complexity of gene therapy manufacturing processes is a significant restraint, as it requires specialized facilities and expertise, increasing production costs and limiting supply

Opportunities2 items

Challenges2 items

Ensuring the long-term safety and efficacy of gene therapies is a significant challenge, as the technology is still evolving and there is limited data on long-term outcomes

The reimbursement landscape for gene therapies is uncertain, with many payers hesitant to cover the high costs of these treatments, limiting access and adoption

Market Segmentation

Loading chart…

Gene Therapy on Cancer Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Viral Gene Therapy

Non-viral Gene Therapy

Regional Insights

Loading chart…

Competitive Landscape

Novartis: regional expansion

Gilead Sciences: innovation pipeline

Amgen: premium pricing

Shanghai Sunway: local manufacturing

Sibiono: OEM tie-ups

CRISPR Therapeutics: vertical integration

Key Gene Therapy on Cancer Companies10 items

Novartis

Gilead Sciences

Amgen

Shanghai Sunway

Sibiono

Segene Inc.

CRISPR Therapeutics

Bluebird Bio

Sangamo Therapeutics

Editas Medicine

Market Ecosystem

Technology providers — develop gene editing tools

Raw material/component suppliers — provide vectors and nucleic acids

System integrators / EPCs — design and manufacture gene therapy products

Distributors / channel partners — facilitate product delivery to healthcare providers

Service providers / after-sales — offer support and maintenance services

End users / buyers — healthcare providers and patients

Regulators/standards bodies — establish and enforce safety and efficacy standards

Recent Industry Insights

Analyst Overview

Table of Contents